Details for Patent: 11,142,528

✉ Email this page to a colleague

Patent 11,142,528 protects BRUKINSA and is included in one NDA.

This patent has thirty-two patent family members in twenty-six countries.

Title:	Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Abstract:	The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby. ##STR00001##
Inventor(s):	Wang; Zhiwei (Beijing, CN), Guo; Yunhang (Beijing, CN)
Assignee:	BEIGENE SWITZERLAND GMBH (Basel, CH)
Application Number:	16/739,447
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form;

These patents are from the daily update and have not yet been integrated into the regular database

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Beigene	BRUKINSA	zanubrutinib	CAPSULE	213217	Nov 14, 2019	RX	Yes	⤷ Try a Trial	Y			⤷ Try a Trial	U-1745	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
Beigene	BRUKINSA	zanubrutinib	CAPSULE	213217	Nov 14, 2019	RX	Yes	⤷ Try a Trial	Y			⤷ Try a Trial	U-2145	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
Beigene	BRUKINSA	zanubrutinib	CAPSULE	213217	Nov 14, 2019	RX	Yes	⤷ Try a Trial	Y			⤷ Try a Trial	U-2537	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Beigene	BRUKINSA	zanubrutinib	CAPSULE	213217	Nov 14, 2019	RX	Yes	⤷ Try a Trial	Y			⤷ Try a Trial	U-2666	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Type	>RLD	>Patent No.	>Product	>Substance	>Delist Req.	>Patent Expiration	>Usecode	>Patented / Exclusive Use

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Beigene	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	⤷ Try a Trial
Beigene	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)	⤷ Try a Trial
Beigene	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA	⤷ Try a Trial
Beigene	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
China	PCT/CN2013/074728	Apr 25, 2013

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014256633	⤷ Try a Trial
Brazil	112015025260	⤷ Try a Trial
Canada	2902686	⤷ Try a Trial
China	104884458	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration